2024-516500-42-00已完成4 期
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Brivaracetam Tablets Ph. Eur. 100 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Briviact (brivaracetam) 100 mg film-coated tablets, Marketing Authorisation Holder: UCB Pharma S.A., Allée de la Recherche 60, B-1070 Bruxelles, Belgium; Manufactured by UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium, in healthy adult, human subjects under fasting condition.
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Arshad Khuroo
Scientific
Sun Pharmaceutical Industries Limited
研究点 (1)
Loading locations...
相似试验
已完成
4 期
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fed condition.Atopic dermatitisPsoriatic arthritisUlcerative colitisRheumatoid arthritis2024-512771-12-00Sun Pharmaceutical Industries Limited32
已完成
4 期
Randomized, Open-label, Single-Dose, Two-treatment, Two-period, Cross-over, Pivotal Bioequivalence Study Comparing Amoxicilin/Clavulanic acid powder for oral suspension 600 mg/42.9 mg/5 mL to Augemntin ES 600 mg/42.9 mg/5 mL powder for oral suspension in Healthy Adult Male and Female Volunteers under Fed Conditions.2023-503233-22-00Tarchominskie Zaklady Farmaceutyczne Polfa S.A.56
已完成
不适用
Pharmacodynamic and pharmacokinetic study of PEG Neutrogen 6 mg subcutaneous injectioCTRI/2015/12/006426Virchow Biotech Private Limited24
已完成
不适用
Pharmacodynamic and pharmacokinetic study of Neutrogen 5 mcg/kg subcutaneous injectioCTRI/2015/12/006415Virchow Biotech Private Limited24
已完成
Unknown
Comparative pharmacokinetic study of two different formulations of Edoxaban under fasting conditions.CTRI/2023/06/054295Zuventus Healthcare Limited40